全文获取类型
收费全文 | 14240篇 |
免费 | 1171篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 436篇 |
妇产科学 | 426篇 |
基础医学 | 1813篇 |
口腔科学 | 343篇 |
临床医学 | 1450篇 |
内科学 | 2814篇 |
皮肤病学 | 119篇 |
神经病学 | 1473篇 |
特种医学 | 478篇 |
外科学 | 2101篇 |
综合类 | 317篇 |
一般理论 | 26篇 |
预防医学 | 1439篇 |
眼科学 | 267篇 |
药学 | 954篇 |
中国医学 | 51篇 |
肿瘤学 | 846篇 |
出版年
2021年 | 103篇 |
2020年 | 93篇 |
2019年 | 157篇 |
2018年 | 156篇 |
2017年 | 129篇 |
2016年 | 142篇 |
2015年 | 201篇 |
2014年 | 242篇 |
2013年 | 462篇 |
2012年 | 608篇 |
2011年 | 709篇 |
2010年 | 381篇 |
2009年 | 370篇 |
2008年 | 695篇 |
2007年 | 744篇 |
2006年 | 790篇 |
2005年 | 779篇 |
2004年 | 775篇 |
2003年 | 763篇 |
2002年 | 778篇 |
2001年 | 252篇 |
2000年 | 268篇 |
1999年 | 293篇 |
1998年 | 193篇 |
1997年 | 160篇 |
1996年 | 135篇 |
1995年 | 175篇 |
1994年 | 132篇 |
1993年 | 152篇 |
1992年 | 270篇 |
1991年 | 232篇 |
1990年 | 203篇 |
1989年 | 197篇 |
1988年 | 226篇 |
1987年 | 197篇 |
1986年 | 187篇 |
1985年 | 204篇 |
1984年 | 216篇 |
1983年 | 152篇 |
1982年 | 185篇 |
1981年 | 162篇 |
1980年 | 143篇 |
1979年 | 150篇 |
1978年 | 137篇 |
1977年 | 127篇 |
1976年 | 94篇 |
1975年 | 111篇 |
1974年 | 123篇 |
1973年 | 107篇 |
1971年 | 93篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Ganz Patricia A. Bandos Hanna Geyer Charles E. Robidoux André Paterson Alexander H. G. Polikoff Jonathan Baez-Diaz Luis Brufsky Adam M. Fehrenbacher Louis Parsons Ann W. Ward Patrick J. Provencher Louise Hamm John T. Stella Philip J. Carolla Robert L. Margolese Richard G. Shibata Henry R. Perez Edith A. Wolmark Norman 《Breast cancer research and treatment》2022,192(1):153-161
Breast Cancer Research and Treatment - The NSABP B-36 compared four cycles of doxorubicin and cyclophosphamide (AC) with six cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100) in... 相似文献
3.
Richard Norman Rebecca Mercieca‐Bebber Donna Rowen John E. Brazier David Cella A. Simon Pickard Deborah J. Street Rosalie Viney Dennis Revicki Madeleine T. King 《Health economics》2019,28(12):1385-1401
The EORTC QLU‐C10D is a new multi‐attribute utility instrument derived from the widely used cancer‐specific quality of life questionnaire, EORTC QLQ‐C30. It contains 10 dimensions (physical functioning, role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems), each with four levels. The aim of this study was to provide U.K. general population utility weights for the QLU‐C10D. A U.K. online panel was quota‐sampled to align the sample to the general population proportions of sex and age (≥18 years). The online valuation survey included a discrete choice experiment (DCE). Each participant was asked to complete 16 choice‐pairs, each comprising two QLU‐C10D health states plus duration. DCE data were analysed using conditional logistic regression to generate utility weights. Data from 2,187 respondents who completed at least one choice set were included in the DCE analysis. The final U.K. QLU‐C10D utility weights comprised decrements for each level of each health dimension. For nine of the 10 dimensions (all except appetite), the expected monotonic pattern was observed across levels: Utility decreased as severity increased. For the final model, consistent monotonicity was achieved by merging inconsistent adjacent levels for appetite. The largest utility decrements were associated with physical functioning and pain. The worst possible health state (the worst level of each dimension) is ?0.083, which is considered slightly worse than being dead. The U.K.‐specific utility weights will enable cost–utility analysis (CUA) for the economic evaluation of new oncology therapies and technologies in the United Kingdom, where CUA is commonly used to inform resource allocation. 相似文献
4.
Gerhart Allyson K. Hecker Markus Janz David M. 《Bulletin of environmental contamination and toxicology》2019,102(3):323-328
Bulletin of Environmental Contamination and Toxicology - Aqueous exposures to selenomethionine (SeMet), the major form of selenium (Se) in the diet, represent a rapid and simplified method for... 相似文献
5.
ABSTRACTObjectives: The consequences of polypharmacy (intake of ≥ 5 drugs) are diverse, including drug interactions, rising costs and side effects. Risk groups for polypharmacy are multimorbid and chronically ill people, such as patients with multiple sclerosis (MS). MS is the most common neuroimmunological disease in young adults worldwide. We aimed to provide a systematic overview of the current research status regarding frequency and predictors of polypharmacy in MS patients.Methods: A systematic literature search in the databases PubMed, Cochrane Library and Scopus was carried out according to the PRISMA guidelines. English and German original research articles were included.Results: Seven studies fulfilled the inclusion criteria of this review, while the research objectives and methods were very heterogenous. The polypharmacy rates in these studies ranged from 15% to 59%. Polypharmacy correlated with comorbidities, increased disability, cognitive deficits, increased hospitalization, higher relapse rate and lower quality of life.Conclusions: In MS patients, polypharmacy is common and closely associated with health issues. There is a great need for research in this area, especially regarding longitudinal changes in drug utilization. Effective networks between physicians and pharmacists are needed to optimize medication management for patients and to achieve the best possible therapy results. 相似文献
6.
7.
Min Dong Liang‐Nan Zeng Qinge Zhang Gabor S. Ungvari Chee H. Ng Helen F. K. Chiu Tian‐Mei Si Kang Sim Ajit Avasthi Sandeep Grover Mian‐Yoon Chong Kok‐Yoon Chee Shigenobu Kanba Min‐Soo Lee Shu‐Yu Yang Pichet Udomratn Roy A. Kallivayalil Andi J. Tanra Margarita M. Maramis Winston W. Shen Norman Sartorius Rathi Mahendran Chay‐Hoon Tan Naotaka Shinfuku Yu‐Tao Xiang 《Psychogeriatrics》2019,19(4):333-339
8.
9.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
10.